Day: August 16, 2024

10:15 London, 12:15 Helsinki, 16 August 2024 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2024    H1/24 H1/232023Revenue EUR million 71.4 95.4 153.7EBITDA EUR million 4.2 15.1 16.6EBIT EUR million 3.1 14.4 15.0Earnings before taxes EUR million 1.9 12.1 12.0Profit EUR million 0.5 10.5 10.0Earnings per share EUR 0.0 0.04 0.04EBITDA margin % 5.9 15.8 10.8EBIT margin % 4.3 15.1 9.8Earnings margin % 0.0 12.7 7.8Personnel (end of period)   588 610 595FIRST HALF 2024 HIGHLIGHTSRevenue decreased by 25.1% to EUR 71.4 (H1/2023: 95.4) million; Processed material sold decreased by 7% to 11,922 (H1/2023: 12,855) tonnes; Tonnage mined increased significantly by 15% to 187,958 (H1/2023: 162,971) tonnes; The Group’s EBITDA was...

BEIJING, Aug. 16, 2024 (GLOBE NEWSWIRE) — Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s adult online education market and China’s adult personal interest learning market, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial and Operational SnapshotsNet revenues were RMB492.2 million (US$67.7 million), compared to RMB526.4 million in the second quarter of 2023. Gross billings (non-GAAP) were RMB383.9 million (US$52.8 million), compared to RMB354.1 million in the second quarter of 2023. Gross profit was RMB415.6 million (US$57.2 million), compared to RMB466.9 million in the second quarter of 2023. Net income was RMB82.3 million (US$11.3 million), compared to RMB173.9 million in the second quarter of 2023. Net income margin1...

Consolidated Interim Report 1 January – 30 June 2024 Company announcement no. 23 – August 16, 2024 Key points from the H1-2024 report (period 1 January – 30 June 2024) On 16 August 2024, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2024 (“H1 2024 report”). The report has not been audited or reviewed. Clinical results The Company’s subsidiary, Reponex Pharmaceuticals A/S (Reponex), reported in company announcement no. 11 of 5 April 2024 very positive final results from the clinical phase 2 proof-of-concept trial of the drug candidate RNX-051, the MEFO study, based on received a high-level summary from Reponex’s clinical...

First half characterized by large adjustments   The action plan is being implemented as a result of major destocking in the distribution chain, continuing high interest rates and historically low housing production – at the same time, we expect a gradual improvement in demand in all three business areas in the second half of the year.  SALES totaled SEK 19,529 (23,479) million ADJUSTED OPERATING PROFIT amounted to SEK 1,185 (3,602) millionADJUSTED PROFIT AFTER NET FINANCIAL ITEMS amounted to SEK 580 (3,355) millionADJUSTED PROFIT AFTER TAX amounted to SEK 257 (2,597) millionEARNINGS per share adjusted for items affecting comparability before and after dilution, based on the average number of shares outstanding during the period, amounted to SEK 0.13 (1.28)ACTION PLAN underway  Press information A media and analysts webcast...

Company Announcement 16 August 2024Announcement No. 28 NKT A/S Q2 2024 Interim Report: 29% organic growth and record quarterly EBITDA NKT CEO Claes Westerlind says: – In Q2 2024, we continued to execute on our high-voltage order backlog and ongoing investments across business lines, while also delivering continued double-digit growth in revenue and EBITDA. Furthermore, we made strong strategic progress, successfully divesting NKT Photonics and completing the acquisition of Portuguese cable manufacturer, SolidAl. NKT’s position as a pure-play cable manufacturer has been strengthened by this acquisition and we remain well positioned to benefit from robust demand across our power transmission and distribution businesses. Financial highlights         EURm Q2 2024 Q2 2023 H1 2024 H1 2023Revenue* 605 468 1,139 890Organic growth 29% 26% 28% 30%Operational...

LOS ANGELES, Aug. 15, 2024 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for fiscal year 2024. Highlights for Fiscal Year Ended May 31, 2024 All comparisons are to the full year of the prior year, unless otherwise noted.Consolidated net sales (revenue) increased 17% to a record $27.5 million compared to $23.5 million in the prior year primarily due to the increase in marketing and sales initiatives in our hearing protection and enhancement segment.  Cost of sales increased by $1,494,386 or 26%, as compared to the comparable period in 2023 due to increases in our branding and marketing...